Data Science: Bridging the Gap Between Controlled Experiment and Real World Data?
Could data science be about to revolutionize the regulatory approval of new drugs?
In June 2018, Cytel created and ran a survey asking respondents from our statistical and statistical programming audience about their views on the potential data science approaches could unlock.
Complete the short form to download your complimentary copy of the report in which we share survey highlights and insights on topics including:
- The main goals and current sources for data science approaches within their organizations
- The key opportunities that data science presents for the industry
- The key barriers and challenges faced by the industry to maximize the potential for healthcare
Real-world evidence (RWE) has historically been used for post-marketing endorsement and in pricing and reimbursement negotiations. But could
data science offer an opportunity to fundamentally shift this
paradigm, leading to better and more affordable medications
being approved on the basis of RWE?